NVIDIA Corp (NVDA) Q4 2025 Earnings Call Highlights: Record Revenue and Data Center Growth Amid ...
Revenue: $39.3 billion for Q4, up 12% sequentially and 78% year on year; fiscal 2025 revenue was $130.5 billion, up 114% from the prior year.
Data Center Revenue: $35.6 billion for Q4, up 16% sequentially and 93% year on year; fiscal 2025 data center revenue was $115.2 billion, more than doubling from the prior year.
Gaming Revenue: $2.5 billion for Q4, decreased 22% sequentially and 11% year on year; full-year revenue was $11.4 billion, up 9% year on year.
Professional Visualization Revenue: $511 million for Q4, up 5% sequentially and 10% year on year; full-year revenue was $1.9 billion, up 21% year on year.
Automotive Revenue: $570 million for Q4, up 27% sequentially and 103% year on year; full-year revenue was $1.7 billion, up 55% year on year.
Gross Margins: GAAP gross margin was 73%, and non-GAAP gross margin was 73.5% for Q4.
Operating Expenses: GAAP operating expenses up 9% sequentially; non-GAAP operating expenses up 11% sequentially.
Shareholder Returns: $8.1 billion returned to shareholders in Q4 through share repurchases and cash dividends.
Q1 Outlook: Expected revenue of $43 billion, plus or minus 2%; GAAP and non-GAAP gross margins expected to be 70.6% and 71%, respectively.
Warning! GuruFocus has detected 3 Warning Signs with NVDA.
Release Date: February 26, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
NVIDIA Corp (NASDAQ:NVDA) reported a record revenue of $39.3 billion for Q4, up 12% sequentially and 78% year-on-year, surpassing their outlook.
Data center revenue for fiscal 2025 was $115.2 billion, more than doubling from the prior year, driven by strong demand for Blackwell and Hopper 200 products.
The Blackwell product ramp is the fastest in the company's history, with $11 billion in revenue generated in Q4 alone.
NVIDIA's inference demand is accelerating, with Blackwell offering up to 25x higher token throughput and 20x lower cost compared to previous models.
Enterprise revenue increased nearly 2x year-on-year, driven by demand for model fine-tuning and AI workflows.
Networking revenue declined 3% sequentially, although it is expected to return to growth in Q1.
Gaming revenue decreased 22% sequentially and 11% year-on-year, impacted by supply constraints.
GAAP gross margins were down sequentially due to the initial deliveries of the Blackwell architecture.
China's data center sales remain well below previous levels due to export controls, with no expected change in the near future.
The complexity and customization of Blackwell systems present challenges in manufacturing and gross margin improvements.
Q: As test-time compute and reinforcement learning show promise, how does this impact the potential for inference-dedicated clusters and NVIDIA's strategy? A: Jensen Huang, CEO, explained that there are multiple scaling laws, including pre-training, post-training, and test-time compute. The demand for post-training and reasoning AI is increasing, requiring more compute power. NVIDIA's architecture is designed to handle these demands, making it versatile for various AI models and ensuring a unified architecture for data centers.
Q: Can you discuss the ramp-up of the GB200 systems and any bottlenecks at the systems level? A: Jensen Huang, CEO, stated that the ramp-up of Grace Blackwell systems has been successful, with significant shipments since CES. Despite the complexity, NVIDIA has managed to scale production effectively, meeting high demand from customers like CoreWeave and Microsoft.
Q: Is Q1 the bottom for gross margins, and what gives you confidence in sustaining strong demand into next year? A: Colette Kress, CFO, noted that gross margins will be in the low 70s during the Blackwell ramp, with improvements expected later in the year. Jensen Huang, CEO, highlighted the ongoing capital investment in data centers and the shift towards AI-based software, which supports sustained demand.
Q: How do you manage the simultaneous ramps of Blackwell and Blackwell Ultra, and is the launch on track? A: Jensen Huang, CEO, confirmed that Blackwell Ultra is set for the second half of the year. The transition from Blackwell to Blackwell Ultra will be smoother due to similar system architectures, and NVIDIA is working closely with partners to ensure a successful rollout.
Q: Can you discuss the balance between custom ASICs and merchant GPUs, and the potential for heterogeneous superclusters? A: Jensen Huang, CEO, emphasized that NVIDIA's architecture is general and flexible, supporting a wide range of AI models and applications. The performance, software ecosystem, and rapid deployment capabilities make NVIDIA's GPUs a preferred choice over custom ASICs.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Apple Rolls Out AI-Driven iOS 26 at WWDC
Apple (NASDAQ:AAPL) kicks off its AI and design revolution with iOS 26, unveiling a Liquid Glass interface and deeper ChatGPT integrations across core apps at WWDC 2025. Apple's vice president of Human Interface Design, Alan Dye, described iOS 26 as the broadest update ever, featuring Liquid Glassa dynamic material that marries glass-like optics with fluid responsivenessapplied universally to iPhone, iPad, Watch, TV and Mac. Native apps from Camera and Safari to Messages and Wallet get fresh layouts that adapt to context, while CarPlay and Maps gain streamlined controls. On the AI front, Apple amplifies its partnership with OpenAI by embedding ChatGPT into Image Playground and Genmoji, letting users generate bespoke images and emojis from text or photoswith full user consent. Visual Intelligence now lets you ask ChatGPT about anything on your screen without switching apps, and Live Translations delivers real-time captions and translations in Messages, FaceTime and Phoneeven with non-iPhone users. Craig Federighi, SVP of Software Engineering, announced expanded Siri personalization and an open Foundation Models Framework that enables any third-party app to tap into Apple Intelligence. Why It Matters: iOS 26's Liquid Glass aesthetic and deep AI mash-up could drive device upgrade cycles and boost services revenue as Apple rolls out paid AI features. It underscores Apple's strategy to monetize AI through its hardware moat rather than by chasing model supremacy. This article first appeared on GuruFocus.
Yahoo
30 minutes ago
- Yahoo
Intel's New Leader Tan Charts Path to Reclaim Chip Dominance
June 9 - Lip-Bu Tan took the helm at Intel (NASDAQ:INTC) this year, bringing a reputation for turnaround success from his 20092021 tenure at Cadence Design Systems (CDNS). When Tan became CEO of Cadence, its shares traded near $5.50. By the time he stepped down, the stock hovered around $186, up roughly 3,200%. That feat suggests his playbook might resonate at Intel, where shares currently trade near $20. Warning! GuruFocus has detected 7 Warning Signs with INTC. Tan has already moved to trim headcount, flatten bureaucracy and refocus on core engineering strengths. He's said Intel must shed non-core assets and sharpen its customer focus, steps likely to improve operating metrics over time. On the AI front, Tan has launched initiatives for AI-optimized hardware and software, backed by new Chief Technology and AI Officer Sachin Katti. Longer term, Intel's existing efforts in quantum computing, like its 12-qubit Tunnel Falls chip, may benefit as larger players such as Alphabet Inc. (NASDAQ:GOOG) and Inc. (NASDAQ:AMZN) seek reliable foundry partners. Intel also stands to gain from U.S. onshoring trends under the current administration. Meanwhile, the emerging humanoid robot market, projected by The Goldman Sachs Group, Inc. (GS) to reach $38 billion by 2035, could offer additional upside if Intel's processors and RealSense depth cameras become standard brains for new robotic systems. Tan's challenge is steep, but his track record suggests Intel may find a path back toward growth and greater investor confidence. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
35 minutes ago
- Yahoo
Iovance Biotherapeutics to Present at Upcoming Conference
SAN CARLOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conference: Goldman Sachs Global Healthcare ConferenceFireside Chat: June 11, 2025 at 1:20 p.m. ETMiami, FL The live and archived webcasts will be available at About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance's Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit Amtagvi ® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. Forward-Looking Statements Certain matters discussed in this press release are 'forward-looking statements' of Iovance Biotherapeutics, Inc. (hereinafter referred to as the 'Company,' 'we,' 'us,' or 'our') within the meaning of the Private Securities Litigation Reform Act of 1995 (the 'PSLRA'). Without limiting the foregoing, we may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'forecast,' 'guidance,' 'outlook,' 'may,' 'can,' 'could,' 'might,' 'will,' 'should,' or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products, including Amtagvi, for which we have obtained U.S. Food and Drug Administration ('FDA') approval, and Proleukin, for which we have obtained FDA and European Medicines Agency ('EMA') approval; the risk that the EMA or other ex-U.S. regulatory authorities may not approve or may delay approval for our marketing authorization application submission for lifileucel in metastatic melanoma; the acceptance by the market of our products, including Amtagvi and Proleukin, and their potential pricing and/or reimbursement by payors, if approved (in the case of our product candidates), in the U.S. and other international markets and whether such acceptance is sufficient to support continued commercialization or development of our products, including Amtagvi and Proleukin, or product candidates, respectively; future competitive or other market factors may adversely affect the commercial potential for Amtagvi or Proleukin; the risk regarding our ability or inability to manufacture our therapies using third party manufacturers or at our own facility, including our ability to increase manufacturing capacity at such third party manufacturers and our own facility, may adversely affect our commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk regarding the successful integration of the recent Proleukin acquisition; the risk that the successful development or commercialization of our products, including Amtagvi and Proleukin, may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain FDA, EMA, or other regulatory authority approval of, or other action with respect to, our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with the FDA, EMA, or other regulatory authorities may support registrational studies and subsequent approvals by the FDA, EMA, or other regulatory authorities, including the risk that the planned single arm Phase 2 IOV-LUN-202 trial may not support registration; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the risk that the changing landscape of care for cervical cancer patients may impact our clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA, EMA, or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA, EMA, or other regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities (including from our prior meetings with the FDA regarding our non-small cell lung cancer clinical trials); the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the risk that we may not be able to recognize revenue for our products; the risk that Proleukin revenues may not continue to serve as a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance, including our financial guidance and projections; the effects of global pandemic; the effects of global and domestic geopolitical factors; and other factors, including general economic conditions and regulatory developments, not within our control. Any financial guidance provided in this press release assumes the following: no material change in our ability to manufacture our products; no material change in payor coverage; no material change in revenue recognition policies; no new business development transactions not completed as of the period covered by this press release; and no material fluctuation in exchange rates. CONTACTS InvestorsIR@ ext. 150 MediaPR@ 650-260-7120 ext. 150Sign in to access your portfolio
